She spent £400 on a serum because the aesthetician told her it would “restore collagen.” She used it faithfully for four months. Her skin looked slightly better, maybe. Or she wanted it to.
At her next dermatology appointment, she asked whether it was working. The dermatologist paused. “Topical collagen cannot penetrate the dermal layer,” she said. “At your age, the bigger driver is hormonal.”
Nobody had told her that. Nobody in the beauty industry was going to.
I built a skincare brand. This is the most counterintuitive thing I will tell you: the most powerful skincare intervention at this life stage is not in a jar.
That is not a reason to abandon your skincare. It is a reason to understand what skincare can and cannot do — and to have a conversation with your doctor that the beauty industry is structurally incentivised not to prompt.
I say this as the founder of Empress Naturals. I say it because I believe it. I say it because when I understood the mechanism of collagen loss in perimenopause — the ERα and ERβ receptor pathways, the MMP enzyme activity, the rate at which structural dermis changes under estrogen withdrawal — I knew that what we were formulating needed to work in concert with hormonal understanding, not instead of it.
Skincare treats the surface. Estrogen builds the structure. Both matter. But confusing one for the other is costing women results they deserve and conversations they’re not having.
Collagen loss in perimenopause is not gradual.
It is accelerated. Up to 30% of dermal collagen is lost in the first five years following menopause. Within the skin, estrogen receptors — specifically ERα and ERβ located in skin fibroblasts — directly regulate collagen production and degradation. When those receptors lose their ligand, the structural biology of the dermis changes at a speed that no topical product, applied to the surface, can fully match.
Understanding this changes not just your skincare choices — it changes the clinical conversation you should be having.
Estrogen receptors in skin are not a cosmetic feature — they are structural architecture
The skin contains two primary types of estrogen receptors: ERα and ERβ. These receptors are concentrated in the dermis — the deeper layer of skin where fibroblasts produce and maintain the structural proteins that give skin its firmness, bounce, and thickness.
Estradiol, acting through these receptors, does three critical things for skin architecture: it upregulates type I and type III collagen production (the primary structural collagens), it stimulates hyaluronic acid synthesis (the molecule responsible for skin hydration and volume), and it suppresses MMP (matrix metalloproteinase) enzyme activity — the enzymes that break collagen down.
As estradiol falls, all three of these functions change simultaneously. Collagen production slows. Hyaluronic acid synthesis declines. MMP activity increases, accelerating collagen degradation. The skin thins, loses elasticity, becomes more prone to wrinkling, and — this is the part rarely mentioned — heals more slowly.
This is not aging. It is the direct consequence of losing estrogenic support in tissue that was architecturally dependent on it.
What topical skincare can do — and the precise boundary of its reach
Topical retinoids (vitamin A derivatives) are among the most evidence-based skincare ingredients available. They stimulate fibroblast activity, upregulate collagen synthesis, and reduce MMP activity — working, mechanistically, in the same direction as estrogen. For perimenopausal and postmenopausal skin, a well-formulated retinoid is not optional. It is doing meaningful structural work.
Peptides signal the dermis to produce collagen. Vitamin C stabilises existing collagen chains and supports synthesis. Hyaluronic acid applied topically improves surface hydration and temporarily plumps. SPF prevents the UV-driven collagen degradation that compounds hormonal loss.
At Empress Naturals, we formulate our AM Serum and Luxe Night Elixir with these mechanisms in mind — including rosehip seed oil, one of the highest natural sources of trans-retinoic acid and essential fatty acids that actively support skin barrier function and lipid replenishment in estrogen-depleted skin.
But here is the boundary of what topical skincare can reach: the dermis. Topical ingredients, applied to the skin surface, do not fully replicate the systemic, receptor-mediated activity of estrogen on fibroblasts. The structural change happening in perimenopause is happening at a depth that topical application cannot fully address. The surface can be supported. The architecture requires a different conversation.
The clinical evidence for systemic estrogen on skin — and what to ask your doctor
The ELITE trial (Early versus Late Intervention Trial with Estradiol) and KRONUS trial data both include skin quality markers — and the evidence is robust: systemic estrogen, appropriately timed, produces measurable improvements in dermal collagen density, skin thickness, and hydration that topical products do not replicate in scope.
This does not mean every woman should be on HRT for her skin. It means that if you are already considering HRT for vasomotor, sleep, or cognitive symptoms, the skin benefits are documented and real — and worth including in the conversation with your clinician. And if skin changes are your most pressing concern and you have been told “just use better skincare,” you may not be getting the full clinical picture.
The combined approach: what this looks like in practice
The most effective skin strategy for perimenopause is not topical or systemic. It is both, understood clearly for what each does.
Topical: a well-formulated retinoid, a vitamin C product used consistently, rigorous daily SPF, and skin-barrier supportive ingredients (ceramides, fatty acids, rosehip seed oil) that address the surface-level consequences of estrogen withdrawal. Our Luxe Night Elixir was designed specifically for the perimenopausal skin barrier — to work with the skin’s reduced self-repair capacity when it is most vulnerable.
Systemic: a clinical conversation about where you are hormonally, what your risk profile supports, and whether systemic estrogen is appropriate for your picture. A dermatologist can address the surface. A menopause specialist addresses the root.
When I first understood how comprehensively estrogen withdrawal affects skin architecture, I felt something close to professional responsibility. Not just as a founder, but as someone who had spent years in the world of skincare watching women invest enormous hope and resources in products that were addressing the right problem from the wrong entry point.
Empress Naturals exists because we believe in evidence-based formulation. But we also believe that a skincare brand that doesn’t tell women the truth about what skincare can’t do is serving its own interests before its customers.
You deserve the full picture. Both parts of it.
Your skin is speaking a hormonal language. Learning to read it is both a beauty decision and a health decision — and the two should not be separated at this life stage.
This week: if you are investing significantly in topical skincare and not yet having a hormonal conversation with a clinician, that is the gap worth closing. Bring the skin changes — not just as a cosmetic concern, but as clinical data about what your estrogen is doing.
At EmpressHealth.ai, our Skin & Hormonal Health module maps your skin changes against your hormonal picture — because your skin is not a separate system. It is a mirror of what is happening underneath.
Both conversations are worth having. Start with whichever one you haven’t had yet.